Hepatic fibrosis represents a process of healing and scarring in response to chronic liver injury. a-Melanocyte-stimulating hormone (a-MSH) is a 13-amino-acid peptide with potent anti-inflammatory effects. We have previously demonstrated that a-MSH gene therapy protects against thioacetamide (TAA)-induced acute liver failure. Therefore, the aim of this study is to investigate whether a-MSH gene therapy possesses antihepatic fibrogenic effect. Liver fibrosis was induced by long-term TAA administration in mice. a-Melanocyte-stimulating hormone expression plasmid was delivered via electroporation after liver fibrosis was established. Our results showed that a-MSH gene therapy attenuated liver fibrosis in TAA-treated mice. Reverse transcription polymerase chain reaction revealed that a-MSH gene therapy attenuated the liver transforming growth factor-b1, collagen a1 and cell adhesion molecule mRNA upregulation. Following gene transfer, the expression of a-smooth muscle actin and cyclooxygenase-2 were both significantly attenuated. Further, a-MSH significantly increased matrix metalloproteinase (MMP), while tissue inhibitors of matrix metalloproteinase (TIMPs) were inactivated. In summary, a-MSH gene therapy reversed established liver fibrosis in mice and prevented the upregulated fibrogenic and pro-inflammatory gene responses after TAA administration. Its collagenolytic effect might be attributed to MMP and TIMP modulation. Hence, a-MSH gene therapy may be an effective therapeutic modality against liver fibrosis with potential clinical use.
Introduction
Thioacetamide (TAA), a selective hepatotoxin, is well known to induce acute and chronic hepatic injury. [1] [2] [3] After administration, it undergoes an extensive metabolism to acetamide and TAA-S-oxide by the mixed function oxidase system. 4 Thioacetamide-S-oxide is further metabolized, at least in part, by cytochrome P-450 monoxygenases to sulfene, TAA-S-dioxide. This TAA-S-dioxide is a very highly reactive compound. 5, 6 Its binding to tissue macromolecules might induce hepatic necrosis and oxidative stress. 7, 8 Oxidative stress may sustain liver fibrosis progression by the activation and morphological change in hepatic stellate cells (HSCs) that include promoting proliferative activity, synthesis and degradation/remodeling of the extracellular matrix (ECM), chemotaxis and proinflammatory activity. 9, 10 In the fibrotic liver, an imbalance takes place between excess synthesis and/or a decrease in the removal of ECM with consequent scarring. 11 The pathophysiology of ECM formation during fibrosis is multifaceted and complex. 12 It involves a change in the expression of ECM proteases (matrix metalloproteinases (MMPs)) or their inhibitors (tissue inhibitors of metalloproteinases (TIMPs)), and an increase in the synthesis of fibronectin and collagens. The process is driven by signaling pathways mediated by proinflammatory cytokines such as transforming growth factor (TGF)-b1 and tumor necrosis factor-a (TNF-a). 13, 14 a-Melanocyte-stimulating hormone (a-MSH) is a 13-amino-acid neuroimmunomodulatory peptide that arises from proteolytic processing of the proopiomelanocortin precursor molecule (POMC). It plays a role in the control of melanogenesis and endocrine metabolism, and has a strong anti-inflammatory effect. 15, 16 A previous study revealed that a-MSH reduces endotoxin-induced liver inflammation. 17 We have also demonstrated that a-MSH gene therapy protects against TAA-induced acute liver failure in mice. 2 A recent report showed that collagen metabolism is a novel target of a-MSH. 18 It attenuated procollagen synthesis in experimental heart transplantation and reduced tubulointerstitial fibrosis in cyclosporine A-induced nephrotoxicity. 19, 20 Besides, a-MSH is known to increase collagenolytic activity by activating MMP-1 and MMP-2.
Suppression of collagen synthesis is a major therapeutic goal in preventing fibrosis. Hence, a-MSH may be a potential therapeutic agent for the treatment of liver fibrosis. Since the elimination half-life of a-MSH is very short, 23 it may be possible to utilize its therapeutic properties to create a gene-based drug treatment modality. In this study, we investigate whether or not electroporative a-MSH gene therapy attenuates TAAinduced hepatic fibrosis in mice.
Results
Long-term a-melanocyte-stimulating hormone expression following electroporative gene transfer There were scanty staining cells for a-MSH in the groups without gene therapy (groups N, I and IV) (Figure 1a , b and e). Strong positive staining cells for a-MSH were detected in the liver following electroporative gene transfer (Figure 1c and d) . The presence of a-MSH in the serum was analyzed using an enzyme-linked immunosorbent assay (ELISA) kit (minimum detectable concentration ¼ 0.15 ng/ml). The serum a-MSH levels in the groups without gene transfer (groups N, I and IV) were all below the detection limit. In contrast, the levels of the a-MSH peptide in circulation in groups II and III remained high with concentrations at 0.2370.04 and 0.3270.05 ng/ml following gene transfer, respectively.
a-Melanocyte-stimulating hormone gene therapy reversed thioacetamide-induced liver fibrosis
There were no significant differences in the volume of food and water intake throughout the entire study period among the groups. After 14 weeks of TAA administration, liver fibrosis could be detected in the histopathology specimens. Sirius red stain in liver sections revealed extensive fibrosis, portal to portal fibrous bridging and nodular transformation in groups I and IV (Figure 2b and e). a-Melanocyte-stimulating hormone gene therapy significantly abrogated hepatic fibrogenesis and reduced matrix density (Figure 2c and d) . This was confirmed by measurement of liver collagen content (Table 1) .
a-Melanocyte-stimulating hormone gene therapy inhibited cell apoptosis in the fibrotic liver Cell apoptosis after liver fibrosis was determined by using terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) study. There was almost no TUNEL staining in the normal control group. Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling-stained positive cells were observed in the fibrotic livers (groups I and IV) (Figure 3b and e). There were remarkably fewer TUNEL-positive cells after gene therapy (Figure 3c and d) .
a-Melanocyte-stimulating hormone gene therapy attenuated cyclooxygenase-2 and proliferating cell nuclear antigen increment after thioacetamide Immunohistochemistry revealed that cyclooxygenase-2 (COX-2) was not detected in the normal group. COX-2 expression was increased after TAA administration (Figure 4b and e). a-Melanocyte-stimulating hormone gene therapy significantly decreased this COX-2 expression (Figure 4c and d) . In addition, cell proliferation was investigated by using proliferating cell nuclear antigen (PCNA) staining. When compared to normal livers, PCNA expression was markedly increased in the TAA-treated livers (Figure 4f and j) . a-Melanocyte-stimulating hormone gene therapy effectively attenuated the PCNA upregulation (Figure 4h and i).
a-Melanocyte-stimulating hormone gene therapy attenuated activated hepatic stellate cell increment after thioacetamide
The expression of the a-smooth muscle actin (a-SMA, marker of activated HSC) increased after chronic TAA administration as measured by immunoblotting The expression of TIMP-1 in the fibrotic livers was also evaluated by RT-PCR, immunohistochemistry and reverse gelatin zymography. Reverse transcription polymerase chain reaction showed that TIMP-1 mRNA was significantly upregulated after chronic TAA administration. a-Melanocyte-stimulating hormone gene therapy (groups II and III) significantly attenuated this increment ( Figure 6 ). Immunohistochemistry revealed that TIMP-1 was increased after chronic TAA administration ( Figure  7g and j). a-Melanocyte-stimulating hormone gene therapy (groups II and III) significantly abrogated this activation (Figure 7h and i). Tissue inhibitors of matrix metalloproteinase activity was determined by reverse gelatin zymography (Figure 8b ). When compared to normal livers, TIMP-1 (28 kDa) was increased in livers after TAA administration. a-Melanocyte-stimulating 
Discussion
Thioacetamide is frequently used as an experimental model of liver damage, which causes hepatitis or cirrhosis, depending on the dose and duration of administration. 2, 3, 24 The induction of oxidative stress is a key feature in the destruction of parenchyma and leads to necrosis, fibrosis and cirrhosis. 9 Liver cirrhosis is considered to be an irreversible process characterized by excess ECM deposition in the liver with scar formation and destruction of the normal liver architecture.
11,12
The a-MSH concentration ranging from 10 to 36 pg/ml is known to increase (26-118 pg/ml) during hepatic encephalopathy in dogs. 25 For this reason, the ELISA kit (minimal detectable concentration ¼ 0.15 ng/ml) failed to detect a-MSH levels in the control and untreated groups. In this study, we have demonstrated that electroporative a-MSH gene therapy provides an effective expression for long-term use. It could reverse establish liver fibrosis and reduce collagen synthesis. a-Melanocyte-stimulating hormone attenuated the activated HSC increment and prevented cell apoptosis in the liver 
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C-H Wang et al after TAA. It also attenuated TGF-b1 and TNF-a gene responses. Transforming growth factor-b1 is a crucial factor during fibrogenesis. 13, 24 A recent study revealed a-MSH abrogate TGF-b1-mediated dermal fibrosis. 18 Thus, TGF-b1 modulation might be involved in a-MSH's collagenolytic effect.
Cyclooxygenase-2 is a key executor of uncontrolled inflammation. 26 Overexpression of COX-2 has been demonstrated in TAA-induced liver fibrosis and postviral human cirrhosis. 27, 28 In addition, COX-2 could contribute to hepatic carcinogenesis by increasing necroinflammatory activity, and by promoting proliferation and enhancing angiogenesis. 29, 30 Selective COX-2 blocker is known to reduce TAA-induced liver fibrosis and attenuate a-SMA expression in hepatic stellate cells. 27, 31 Hence, COX-2 might be a novel therapeutic target to prevent liver cirrhosis. a-Melanocyte-stimulating hormone is known to inhibit COX-2 expression after endotoxin-induced inflammation. 32, 33 Therefore, a-MSH gene therapy might exert antihepatic fibrogenesis through COX-2 modulation.
Proliferating cell nuclear antigen is a stable cell cyclerelated nuclear protein that is increasingly expressed in late G1 and throughout S phases of the cell cycle. The expression of PCNA is correlated with cell proliferation and represents a reliable marker for proliferative activity. 34 Proliferating cell nuclear antigen and other cell-cycle-related proteins are upregulated in TAAinduced liver cirrhosis in rats. 35 High PCNA expression is associated with high incidence of hepatocellular carcinoma in cirrhotic patients. 36 a-Melanocyte-stimulating hormone is known to modulate cell-cycle-related molecules (cyclin G1 and cyclin-dependent kinase-7) in experimental heart transplantation. 19 In this study, we have shown that PCNA levels increase in the TAAtreated livers. a-Melanocyte-stimulating hormone gene therapy, however, attenuated the PCNA expression in fibrotic livers. It might be inferred from this observation that a-MSH may reduce the risk of carcinogenesis in fibrotic livers.
Cell adhesion molecules are known as prognostic markers of liver fibrosis. 37 The expressions of ICAM-1 
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and VCAM-1, modulated by TNF-a, are upregulated in alcoholic hepatitis, carbon tetrachloride-induced liver injury and nutritional fibrosis. [38] [39] [40] In a previous study, it was shown that a-MSH attenuates lipopolysaccharideinduced vasculitis by downregulating cell adhesion molecule expression. 41 Therefore, cell adhesion molecule modulation might be involved in a-MSH's antifibrotic effects.
Imbalance between MMPs and TIMPs in the ECM contributes to the pathogenesis in liver fibrosis. 42 Hepatic stellate cells are the major sources of MMPs and TIMPs. However, hepatocytes are known to participate actively in the ECM modulation. 43 MMP activity is regulated by the TIMPs, which bind in substrate-and tissue-specific manners to MMPs, blocking their proteolytic activity. 44 During fibrosis, TIMP mRNA and protein levels dramatically increase, while MMP levels increase modestly or remain relatively static. 45, 46 Studies have shown that MMP-1 and MMP-8 gene therapy can ameliorate experimental rat liver fibrosis. 47, 48 Recently, a report suggested that intracellular MMP-1 may confer resistance to apoptosis. 49 However, its role during liver fibrosis needs to be elucidated. Further, studies suggest that antibody and antisense oligonucleotide directed to TIMP-1 attenuate rat liver fibrosis. 44, 50 Therefore, the interplay between MMPs and TIMPs provides a reference point for regulation to develop therapies to treat patients with ongoing fibrosis. In the present study, we have shown that a-MSH gene therapy reversed established liver cirrhosis through increased MMP activation and by suppressing TIMP. Hence, matrix degradation manipulation might be involved in a-MSH's antifibrotic effects.
In brief, we have clearly demonstrated that a-MSH gene therapy reversed established liver fibrosis in mice. It also attenuated the fibrogenic, proinflammatory and cell adhesion molecule gene responses after TAA administration. Its collagenolytic effect may be attributed to MMP and TIMP modulation. In conclusion, a-MSH gene therapy may be a novel treatment modality for liver cirrhosis with potential clinical use.
Materials and methods

a-Melanocyte-stimulating hormone expression plasmid preparation
We used recombinant a-MSH-expressed plasmid (Zycos Inc., Lexington, MA, USA). 51 In brief, the fusion construct that encoded the 13 amino acids of a-MSH inframe with a four-amino-acid extension (GGC AAG AAG CGG -ACTH 14 -17) as amidation sequence was cloned. This fusion construct was driven by a human cytomegalovirus promoter (pCMV-ACTH 1 -17). A pCMV-LacZ was used as a vehicle control. These plasmids were purified using the EndoFree Plasmid Giga Kit (Qiagen, Valencia, CA, USA).
Liver fibrosis induction and a-melanocyte-stimulating hormone gene therapy Male 6-to 8-week-old ICR mice were purchased from the National Science Council, Taiwan and kept in Kaohsiung Chang Gung Memorial Hospital Animal Facility under standard temperature, and light and dark cycles. All procedures performed were approved by the Kaohsiung Chang Gung Memorial Hospital Animal Care and Use Committee. Hepatic fibrosis was induced by incorporating 300 mg/l TAA (Sigma-Aldrich, St Louis, MO, USA) in the drinking water of the mice for an 18-week period modified from a previous study. 3 In all, 16 mice were killed at the end of 14 weeks for liver fibrosis confirmation (group I).
To evaluate the antifibrotic effect of a-MSH, gene therapy administration was started at the end of 14 weeks. Briefly, 30 ml bovine hyaluronidase (0.4 IU/ml) (Sigma-Aldrich, St Louis, MO, USA) was injected into the anterior tibialis (AT) muscle of the mice 2 h before electroporation. Plasmid (pCMV-ACTH 1-17) was injected into the bilateral AT muscle using a 27-G needle (30 ml at each leg, 4 mg/ml) (group II, n ¼ 16). Electroporation was delivered by electrical pulses (eight pulses 
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Another 32 mice were gene electrotransferred using the same procedure as described above using pCMV-ACTH 1-17 (group III, n ¼ 16) or pCMV-LacZ (group IV, n ¼ 16) at the end of 14 and 16 weeks. All mice (group II-IV) were killed at the end of the18-week TAA induction. Five mice were killed before TAA intoxication as normal control (group N).
Serum a-MSH level and liver collagen content measurement
To analyze a-MSH expression after gene transfection, blood samples were collected at 0, 14 and 18 weeks after TAA induction. The amount of plasma a-MSH was measured using an ELISA kit (Phoenix Pharmaceuticals, Belmont, CA, USA) according to the user's manual as in a previous study. 2 For liver collagen content, the Sircol collagen assay (Biocolor, Belfast, UK) was performed following the manufacturer's instructions as described. 3, 53 Briefly, 50 mg of liver was homogenized, and total acid pepsin-soluble collagens were extracted overnight using 5 mg/ml pepsin in 500 ml of 0.5 M acetic acid. Sircol dye reagent (1 ml) was added to 100 ml of each sample, in duplicate, and incubated at 251C for 30 min. After centrifugation, the pellet was suspended in 1 ml of alkali reagent, and absorbance was read at 540 nm.
Histopathology and immunohistochemistry
For liver histopathology, mice were killed at 0, 14 and 18 weeks after TAA induction. The liver was removed and fixed. Paraffin-embedded sections (5 mm) were stained with 0.1% sirius red in picric acid (Sigma-Aldrich) with matrix density quantified by a computerized image analysis system as in previous studies. 3 For immunohistochemistry, sections were incubated with a-MSH antiserum (Chemicon, Temecula, CA, USA), PCNA, COX-2, MMP-1 and TIMP-1 antibody (Abcam, Cambridge, MA, USA). Immunoreactivity was visualized using the Vectastain Elite ABC Peroxidase method (Vector Laboratories, Burlingame, CA, USA) and diaminobenzidine as the chromagen. In addition, apoptosis in the liver was detected by TUNEL staining using an apoptosis detection kit (Oncogene Research Products, Cambridge, MA, USA). Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling was performed according to the manufacturer's instructions.
Immunoblotting of a-smooth muscle actin
Liver specimens harvested at 0, 14 and 18 weeks after TAA induction were homogenized in a lysis buffer with complete protease inhibitor cocktail tablets (Roche, Mannheim, Germany). For analysis of a-SMA, 20 mg of protein extracts were electrophoresed on a 10% acrylamide SDS-polyacrylamide gel electrophoresis (PAGE) gel and immunoblotted onto PVDF membranes. Membranes were blocked for 1 h at room temperature and incubated overnight with a-SMA and a-tubulin antibodies (Abcam). Antibody binding was detected using a horseradish peroxidase (HRP)-linked IgG. Bands were visualized using an ECL detection system (AmershamPharmacia Biotech, Little Chalfont, UK). a-Tubulin was used as internal control. Band intensities were quantified by using an image analyzer (Densitograph AE-6900M, Atto, Tokyo, Japan).
Reverse transcription-polymerase chain reaction
Liver specimens were harvested at 0, 14 and 18 weeks after TAA induction. The expressions of TGF-b1, collagen a1, fibronectin, TNF-a, ICAM-1, VCAM-1, MMP-1, MMP-8 and TIMP-1 mRNA were analyzed using the RT-PCR technique. Total RNA was extracted from harvested tissues with chloroform and the TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and then reverse-transcribed into cDNA. PCR was performed at a final concentration of 1 Â PCR buffer, 1 mM each of the 3 The other primer sequences were as described previously.
3 Amplification products were separated by agarose gel electrophoresis and visualized by ethidium bromide staining. The gel was scanned at a NucleoVision imaging workstation (NucleoTech, San Mateo, CA, USA) and quantified using GelExpert release 3.5.
Gelatin and reverse gelatin zymography
Gelatin zymography was studied to explore MMP activity. Briefly, liver tissues were homogenized in a protein extraction buffer. The supernatant of a centrifuged liver sample (20 mg of protein extract per line) was mixed 1:3 with a sample buffer and separated by SDS-PAGE in 8% polyacrylamide gel copolymerized with 1 mg/ml gelatin (Sigma-Aldrich) as described. 22, 54 Gels were incubated at 371C overnight in an MMP activation buffer. After Coomassie blue staining, the extent of gel digestion localized to bands of different MMPs was quantified by densitometry. For TIMP activity, reverse gelatin zymography was similarly performed, with the exception that conditioned medium from baby hamster kidney (BHK) cells, which express gelatinase, was included in the 12% polyacrylamide gel mix with the gelatin (1 ml of conditioned medium was added to 15 ml of the gel mix). 55 All washes and incubations were the same as gelatin zymography. After regeneration, the gelatinase degraded the gelatin in all regions of the gel except in regions where there was TIMP activity. NIH3T3 cells were used as positive control. NIH3T3 and BHK cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA).
Statistical analysis
All data were presented as mean7s.e.m. (at least three separate experiments). Statistical analyses were performed using one-way ANOVA followed by t-test. P-values less than 0.05 were considered significant. a-MSH gene transfer attenuates hepatic fibrosis C-H Wang et al
